Skip to main content

Advertisement

Table 3 Comprehensive list of PD-L1 inhibitors and PD-1 inhibitors with antibody class and immune adverse events. This table shows the similarities and differences between PD-1/PD-L1 inhibitors

From: Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Target Drugs Antibody class Immune-related adverse events
PD-L1 Atezolizumab IgG1 Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), meningitis/encephalitis, pancreatitis, dermatitis/rash
Durvalumab IgG1 Pneumonitis, hepatitis, colitis, endocrinopathies (thyroid disease, adrenal insufficiency, hypophysitis, type 1 diabetes), nephritis
Avelumab IgG1 Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction
Envafolimab IgG1 Increased aspartate aminotransferase, increased alanine aminotransferase, lymphopenia
BMS-936559 IgG4 Hypothyroidism, hepatitis, sarcoidosis, endophthalmitis, diabetes mellitus, myasthenia gravis
CK-301 IgG1 N/A (ongoing)
CS-1001 IgG4 Anemia, increased blood bilirubin, protein urine present, white blood cell count decreased, proteinuria
SHR-1316 IgG4 N/A (ongoing)
CBT-502 IgG1 N/A (ongoing)
BGB-A333 IgG1 variant N/A (ongoing)
PD-1 Nivolumab IgG4 Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction, encephalitis, rash
Pembrolizumab IgG4 Pneumonitis, hepatitis, colitis, endocrinopathies, nephritis, renal dysfunction
Cemiplimab IgG4 Cellulitis, pneumonitis, hypercalcemia, pleural effusion